Press Release Archive

10.12.2022

Pfizer and BioNTech Receive U.S. FDA Emergency Use Authorization for Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine Booster in Children 5 Through 11 Years of Age

10.05.2022

Pfizer Completes Acquisition of Global Blood Therapeutics 

10.04.2022

Voyager Therapeutics Announces Pfizer License of Next-Generation AAV Capsid for Rare Neurologic Disease Target

10.04.2022

Pfizer Announces Positive Topline Results from Phase 3 TALAPRO-2 Trial

10.03.2022

Pfizer Completes Acquisition of Biohaven Pharmaceuticals

09.26.2022

Pfizer and BioNTech Submit Application to U.S. FDA for Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent Vaccine Booster in Children 5 Through 11 Years of Age

09.22.2022

Pfizer Declares Fourth-Quarter 2022 Dividend

09.22.2022

Pfizer to Supply Global Fund Up to 6 Million PAXLOVID™ Treatment Courses for Low-and-Middle-Income Countries

09.20.2022

Pfizer Invites Public to View and Listen to Webcast of November 1 Conference Call with Analysts

09.20.2022

CytoReason Announces Expanded Collaboration Deal with Pfizer to Deliver AI for Drug Discovery and Development

09.19.2022

Pfizer Announces Positive Top-Line Results from Phase 3 Study in 20-Valent Pneumococcal Conjugate Vaccine in Infants in the European Union

09.15.2022

Pfizer Announces Positive Top-Line Results from Phase 3 Trial of Pentavalent Meningococcal Vaccine Candidate (MenABCWY) in Adolescents